Tolvaptan, an oral vasopressin V2 receptor antagonist for heart failure?

被引：0
|
作者：
Greenberg, Arthur [1 ]
机构：
[1] Duke Univ, Dept Med, Div Nephrol, Med Ctr, Durham, NC 27710 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2007年 / 50卷 / 06期
关键词：
D O I：
10.1053/j.ajkd.2007.10.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：904 / 907
页数：4
相关论文
共 50 条
  • [21] Determinants of Urine Volume in ADPKD Patients Using the Vasopressin V2 Receptor Antagonist Tolvaptan
    Kramers, Bart J.
    van Gastel, Maatje D. A.
    Boertien, Wendy E.
    Meijer, Esther
    Gansevoort, Ron T.
    AMERICAN JOURNAL OF KIDNEY DISEASES, 2019, 73 (03) : 354 - 362
  • [22] Structural basis of tolvaptan binding to the vasopressin V2 receptor
    Liu, Hong-li
    Zhong, Hai-yang
    Zhang, Yi-xiao
    Xue, Hua-rui
    Zhang, Zheng-shuo
    Fu, Ke-quan
    Cao, Xu-dong
    Xiong, Xiao-chun
    Guo, Dong
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (11) : 2441 - 2449
  • [23] Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, enhances aquaresis and renal hemodynamics compared to furosemide in mild to moderate heart failure
    Costello-Boerrigter, LC
    Burnett, JC
    Smith, WB
    Ouyang, J
    Zimmer, CA
    Orlandi, C
    EUROPEAN HEART JOURNAL, 2004, 25 : 451 - 451
  • [24] Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan
    Kuragaichi, Takashi
    Sato, Yukihito
    ESC HEART FAILURE, 2021, 8 (01): : 527 - 538
  • [25] DETERMINANTS OF URINE VOLUME IN ADPKD-PATIENTS USING THE VASOPRESSIN V2 RECEPTOR ANTAGONIST TOLVAPTAN
    Kramers, Bart
    Heida, Judith
    Boertien, Wendy
    van Gastel, Maatje
    Meijer, Esther
    Gansevoort, Ron
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2018, 33
  • [26] Vasopressin V2 Receptor Antagonist Tolvaptan Prevents The Development of Chronic Heart Failure via Its Anti-inflammatory and Anti-fibrotic Actions
    Yamazaki, Takanori
    Izumi, Yasukatsu
    Nakamura, Yasuhiro
    Yamaguchi, Takehiro
    Hanatani, Akihisa
    Shimada, Kenei
    Iwao, Hiroshi
    Yoshiyama, Minoru
    CIRCULATION, 2012, 126 (21)
  • [27] THE EFFECTS OF A VASOPRESSIN V2 RECEPTOR ANTAGONIST IN THE MANAGEMENT OF PATIENTS WITH CIRRHOSIS AND HYPONATREMIA. SAFETY AND EFFICACY OF ORAL TOLVAPTAN IN THE SALT TRIALS
    Cardenas, Andres
    Gines, Pere
    Marotta, Paul
    Czer-wiec, Frank S.
    Ouyang, John
    Sexton, Anne
    Guevara, Monica
    Afdhal, Nezam H.
    HEPATOLOGY, 2009, 50 (04) : 467A - 468A
  • [28] Use of Oral Vasopressin V2 Receptor Antagonist for Hyponatremia in Acute Brain Injury
    Jeon, Sang-Beom
    Choi, H. Alex
    Lesch, Christine
    Kim, Myung Chun
    Badjatia, Neeraj
    Claassen, Jan
    Mayer, Stephan A.
    Lee, Kiwon
    EUROPEAN NEUROLOGY, 2013, 70 (3-4) : 142 - 148
  • [29] Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist, tolvaptan
    Furukawa M.
    Umehara K.
    Kashiyama E.
    Cardiovascular Drugs and Therapy, 2011, 25 (Suppl 1) : S83 - S89
  • [30] Effects of tolvaptan (OPC-41061), a vasopressin V2 receptor antagonist, and furosemide on hemodynamics, renal functions, serum electrolytes, and neurohormones in dogs with and without heart failure
    Onogawa, T
    Yamamura, Y
    Nakamura, S
    Nakayama, S
    Fujiki, H
    Mori, T
    CIRCULATION, 2004, 110 (17) : 21 - 21
12345